ID   KH OS R3
AC   CVCL_T433
DR   cancercelllines; CVCL_T433
DR   Wikidata; Q54899848
RX   PubMed=17096323;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 11808; Kirsten murine sarcoma virus (Ki-MSV).
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_T432 ! KH OS R2
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 11
//
RX   PubMed=17096323; DOI=10.1002/ijc.22327;
RA   Lourda M., Trougakos I.P., Gonos E.S.;
RT   "Development of resistance to chemotherapeutic drugs in human
RT   osteosarcoma cell lines largely depends on up-regulation of
RT   clusterin/apolipoprotein J.";
RL   Int. J. Cancer 120:611-622(2007).
//